• About Us
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Focus Areas
    • Collaborations
  • Our Science
    • Our Pipeline
    • QLS-111
    • Publications & Posters
  • News and Events
  • Careers
  • Contact Us
  • Skip to main content
Qlaris Bio

Qlaris Bio

Careers Contact Us
News and Events

News and Events

VIEW:

  • All
  • News
  • Event

An Interview With Our Founders, Thurein Htoo and Dr. Barbara Wirostko, On The Apteryx and Osprey Clinical Studies

NewsApril 29, 2025

Interviewed by Carey Powers of Powers & Company at the Glaucoma 360 New Horizons Forum 2025.

Read More about An Interview With Our Founders, Thurein Htoo and Dr. Barbara Wirostko, On The Apteryx and Osprey Clinical Studies

Qlaris Bio Announces Positive Topline Data From Two Phase II Trials Of QLS-111 In Patients With Primary Open Angle Glaucoma And Ocular Hypertension

NewsFebruary 5, 2025

QLS-111 met all primary and secondary endpoints in the Osprey and Apteryx studies QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass. — February 5, 2025 — Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results […]

Read More about Qlaris Bio Announces Positive Topline Data From Two Phase II Trials Of QLS-111 In Patients With Primary Open Angle Glaucoma And Ocular Hypertension

Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma

NewsApril 30, 2024

Financing led by Canaan and New Leaf Venture Partners, and includes funds managed by abrdn Inc., Correlation Ventures, and Mayo Clinic Ventures DEDHAM, Mass. — April 30, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round. […]

Read More about Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma

Qlaris Bio’s Novel IOP-Lowering Product, QLS-111, Is Dosed In Phase II Trials

NewsApril 2, 2024

A first-in-class product, QLS‑111 is designed to lower intraocular pressure (IOP) beyond currently achievable levels in patients with glaucoma by targeting episcleral venous pressure (EVP) DEDHAM, Mass. — April 2, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate […]

Read More about Qlaris Bio’s Novel IOP-Lowering Product, QLS-111, Is Dosed In Phase II Trials

An Interview With Dr. Shan Lin – Unmet Needs in Glaucoma & New Treatments On The Horizon

NewsApril 2, 2024

Please click below for an interview with Dr. Shan Lin, co-research director of the Glaucoma Center of San Francisco and a member of the Scientific Advisory Board of Qlaris Bio – Interviewed by Carey Powers of Powers & Company at the Glaucoma 360 New Horizons Forum 2024.

Read More about An Interview With Dr. Shan Lin – Unmet Needs in Glaucoma & New Treatments On The Horizon

Qlaris Bio Named 2022 Scrip Awards Finalist for Biotech Company of the Year 

NewsOctober 4, 2022

Annual awards program recognizes innovations and achievements in global biopharma Wellesley, Mass., September 28, 2022 – Qlaris Bio, Inc, a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today it has been named a finalist in the WuXi AppTec’s Biotech Company of the Year category of the 2022 Scrip Awards. Qlaris has seen […]

Read More about Qlaris Bio Named 2022 Scrip Awards Finalist for Biotech Company of the Year 
  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Qlaris Bio, Inc. © 2023 All Rights Reserved Privacy Policy | Terms of Use | Accessibility Statement